Hypomethylating agents (azacitidine, decitabine)
Low-intensity chemotherapy that strips chemical 'off' switches (methyl groups) from DNA so silenced genes can be read again. The mainstay for older patients with AML and high-risk MDS, especially combined with venetoclax.
Azacitidine and decitabine (approved 2004-06) extend survival in higher-risk MDS and were the only option for AML patients unfit for intensive chemotherapy until venetoclax-azacitidine (VIALE-A, 2020) roughly doubled responses and became the standard, now available fully orally. They are given in outpatient cycles for as long as they work; 'HMA failure' defines a population with very poor outcomes where menin inhibitors, IDH inhibitors and trials of new agents are focused. Response can take several cycles, so early stopping is a common error.
Pages like this
not linked directly; found by shared links- InstitutionUSC Norris Comprehensive Cancer Center
Shares Azacitidine, Myelodysplastic syndromes / neoplasms (MDS), Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.
- PersonStephen B. Baylin
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.
- IdeaShorter venetoclax courses in unfit AML
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia.
- ProductDecitabine + cedazuridine (oral)
Shares Myelodysplastic syndromes / neoplasms (MDS), Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax, Acute myeloid leukaemia.
- PairingVenetoclax + hypomethylating agent
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia.
- PairingMenin inhibitor + venetoclax + azacitidine
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia.
- TrialVIALE-A
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia.
- Key paperAGILE: ivosidenib plus azacitidine for newly diagnosed IDH1-mutated AML in patients unfit for intensive chemotherapy
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia.